MARKET

INMB

INMB

INMUNE BIO, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.38
-0.42
-5.38%
Opening 11:35 10/30 EDT
OPEN
7.84
PREV CLOSE
7.80
HIGH
7.84
LOW
7.34
VOLUME
32.41K
TURNOVER
--
52 WEEK HIGH
24.42
52 WEEK LOW
2.200
MARKET CAP
99.25M
P/E (TTM)
-8.3117
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
INmune Bio, Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on Thursday, November 5
Management to host conference call at 4:30 pm ET on that dayLA JOLLA, Calif, Oct. 29, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Thursday, November 5, 2020 at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2020 and to provide a corporate update.Conference Call InformationTo participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter Conference Call when reaching an operator.Date: November 5, 2020 Time: 4:30 PM Eastern Time Participant Dial-in: 800-909-4145 Participant Dial-in (international): 415-226-5358A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through November 12 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 21970461.About INmune Bio, Inc.INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently in clinical trials to determine if it can help treat for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and treatment resistant depression (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.Forward Looking Statements The Company’s clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, LIVNate, Quellor™ and INKmune are still in clinical trials or preparing to start clinical trials and have not been approved and there cannot be any assurance that they will be approved or that any specific results will be achieved. Our two platforms are beginning clinical trials and there cannot be any assurance of the success of these trials. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.INmune Bio Contact: David Moss, CFO (858) 964-3720 DMoss@INmuneBio.comInvestor Contact: Chuck Padala LifeSci Advisors, LLC (917) 741-7792 Chuck@lifesciadvisors.com
GlobeNewswire · 1d ago
Do Insiders Own Lots Of Shares In INmune Bio, Inc. (NASDAQ:INMB)?
A look at the shareholders of INmune Bio, Inc. (NASDAQ:INMB) can tell us which group is most powerful. Insiders often...
Simply Wall St. · 4d ago
INmune Bio to present interim data from early-stage Alzheimer’s study
INmune Bio ([[INMB]] +4.2%) announces data presentation from Phase Ib study of XPro1595 in patients with Alzheimer’s. Data were presented at International Conference on Alzheimer’s Drug Discovery meeting.The Phase Ib study continues
Seekingalpha · 10/05 15:44
INmune Bio to present preliminary phase I data on Alzheimer’s drug discovery
INmune Bio ([[INMB]] +4.2%) announces that CJ Barnum PhD, Head of Neurosciences will present data from a Phase Ib study of a biomarker directed XPro1595 in patients with Alzheimer’s disease.
Seekingalpha · 10/05 15:44
INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimers Drug Discovery
LA JOLLA, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced  that CJ Barnum PhD, Head of Neurosciences will present
GlobeNewswire · 10/05 14:00
INmune Bio Reports Co. Head Of Neurosciences To Present Data From Ongoing Biomarker Directed Phase 1b Study Of Neuroinflammation In Patients With Alzheimer's At 11:20 a.m. EDT Today At International Conference on Alzheimer's Drug Discovery
INmune Bio, Inc. (NASDAQ:INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today
Benzinga · 10/05 13:07
INmune Bio, Inc. to Host Key Opinion Leader Webinar on Treatment Resistant Depression on Tuesday, September 29
LA JOLLA, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc.(NASDAQ:INMB) (the "Company"), a clinical-stage immunology company focused ondeveloping treatments that harness the patient's innate
Benzinga · 09/23 10:03
INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595 in Patients with Treatment Resistant Depression
100 patient blinded, randomized, biomarker-directed Phase 2 study will use neuroimaging technology to study the complex biology of treatment resistant diseaseStudy supports INmune Bio’s approach to treating inflammation as a common mechanism in neurologic diseaseAccompanying Key Opinion Leader webinar
GlobeNewswire · 09/16 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INMB. Analyze the recent business situations of INMUNE BIO, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INMB stock price target is 21.25 with a high estimate of 26.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 21
Institutional Holdings: 359.05K
% Owned: 2.67%
Shares Outstanding: 13.45M
TypeInstitutionsShares
Increased
5
43.08K
New
9
-9.29K
Decreased
3
17.91K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About INMB
Inmune Bio Inc. is a clinical-stage pharmaceutical immunotherapy company. The Company is focused on developing strategies for oncology that focus on re-engineering and harnessing the innate immune system to treat the patient’s cancer. The Company’s product candidates (INMB) target cells of the innate immune system that include natural killer cells (NK cells) and myeloid derived suppressor cells, (MDSC cells). The NK cell of the innate immune system has two primary functions, such as to kill virally infected cells and to kill cancer cells. Its INB03 is a protein biologic that has beneficial effects in patients with cancer. Its initial focus is on its ability to inhibit proliferation and function of myeloid-derived suppressor cells (MDSC).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of INmune Bio Inc stock information, including NASDAQ:INMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INMB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INMB stock methods without spending real money on the virtual paper trading platform.